Our Products
PTC has delivered a number of firsts for patients who previously had no other treatment options. Our strategy leverages our innovative scientific knowledge, our deep therapeutic expertise and robust global commercial infrastructure.
Please note, our products are approved in individual countries for specific uses and the information provided is governed by local regulations. The name, availability and indication of these medicines may vary by country.
Evrysdi® (risdiplam) is a product from the SMA collaboration between PTC, the SMA Foundation and Roche. Evrysdi is marketed in the United States by Genentech, a member of the Roche Group, and marketed in rest of world by Roche.
PTC Therapeutics has exclusive rights from Akcea Therapeutics Inc., now Ionis Pharmaceuticals to commercialize Tegsedi® (inotersen) and Waylivra® (volanesorsen) in Latin America and certain Caribbean countries.
U.S. Expanded Access Policy
At PTC we are committed to providing novel treatment options to patients living with serious diseases. To do this, we conduct clinical trials to assess the safety and efficacy of investigational medicines, which may allow us to obtain the necessary regulatory approvals and provide patients with broader access to these medicines.
Leveraging our expertise and cutting-edge biotechnology platforms, we’re urgently turning the latest scientific advances into purposeful treatments
We're committed to making progress in rare disease through clinical trial research, each and every moment of every day